bluebird bio (BLUE) –
-
BLUEBIRD BIO, INC. (NASDAQ: BLUE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
BLUE Lawsuit: Robbins LLP Reminds Investors of bluebird bio, Inc. of Pending Lead Plaintiff Deadline
-
Form 8-K bluebird bio, Inc. For: Apr 16
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
BLUEBIRD BIO, INC. (NASDAQ: BLUE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against bluebird bio, In
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Form SC 13G/A bluebird bio, Inc. Filed by: STATE STREET CORP
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
bluebird bio, Inc. (BLUE) Class Action Notice: Robbins LLP Reminds Stockholders of Lead Plaintiff Deadline in Class Action Against bluebird bio, Inc.
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Blue, and Luna Innovations and Encourages Investors to Contact the Firm
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
BLUEBIRD BIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (NASDAQ: BLUE)
-
BLUE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm
-
BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead the bluebird bio Class Action Lawsuit
-
BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm
-
bluebird bio (BLUE) PT Lowered to $3 at Wells Fargo
-
bluebird bio (BLUE) PT Lowered to $1 at Goldman Sachs
-
bluebird bio (BLUE) Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
-
Form 8-K bluebird bio, Inc. For: Mar 24
-
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
-
Form NT 10-K bluebird bio, Inc. For: Dec 31
-
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
-
bluebird bio (BLUE) PT Lowered to $1.68 at Wedbush
-
bluebird bio (BLUE) Secures up to $175 Million Debt Financing with Hercules Capital
-
Form 8-K bluebird bio, Inc. For: Mar 15
-
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
-
bluebird bio (BLUE) Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
-
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
-
Form 4 bluebird bio, Inc. For: Mar 01 Filed by: Obenshain Andrew
-
Form 4 bluebird bio, Inc. For: Mar 01 Filed by: Krawtschuk Christopher
-
Form 4 bluebird bio, Inc. For: Mar 01 Filed by: Colvin Richard A
-
Form 4 bluebird bio, Inc. For: Mar 01 Filed by: Vittiglio Joseph
-
Form 4 bluebird bio, Inc. For: Mar 01 Filed by: Klima Thomas J
-
bluebird bio (BLUE) PT Lowered to $1.02 at HSBC
-
Form SC 13G/A bluebird bio, Inc. Filed by: PFM Health Sciences, LP
-
Form SC 13G/A bluebird bio, Inc. Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G bluebird bio, Inc. Filed by: Alyeska Investment Group, L.P.
-
Form SC 13G bluebird bio, Inc. Filed by: Granahan Investment Management, LLC
-
Form SC 13G/A bluebird bio, Inc. Filed by: VANGUARD GROUP INC
-
bluebird bio (BLUE) PT Raised to $36.50 at BofA Securities
-
Form SC 13G bluebird bio, Inc. Filed by: GOLDMAN SACHS GROUP INC
Back to BLUE Stock Lookup
